FDA Update – September/October 2012
News from the FDA on bosutinib (Bosulif), ziv-aflibercept (Zaltrap), and everolimus oral suspension tablets (Afinitor Disperz).
News from the FDA on bosutinib (Bosulif), ziv-aflibercept (Zaltrap), and everolimus oral suspension tablets (Afinitor Disperz).
Differences in the impact of aspirin in various forms of cancer are highlighted in two studies recently published in the oncology literature.
Earlier study findings that anthracycline- or trastuzumab-based treatment for breast cancer raises the risk for heart failure and cardiomyopathy can be extended to a more general population of women.
The ruling preserves vital provisions that are already improving the ability of people with cancer to access needed care.
Oncologists at M.D. Anderson Cancer Center found the key to screening for pancreatic cancer lies in the interpretation of preoperative CT scans.
The grief experienced by the oncologists had unique elements beyond sadness, crying, and sleep loss.
People with cancer and their caregivers can turn to a new Web site to help answer the question from concerned relatives and friends, “What can I do to help?”
News about pertuzumab injection (Perjeta); ondansetron (Zofran); carfilzomib (Kyprolis); Therascreen KRAS RGQ PCR Kit; Prostate Health Index (phi); and Prepopik
Research results suggest that of the billions of cancer cells that exist in a patient, only about one in a million is resistant to drugs using targeted therapy.
Drug Safety Communication on lenalidomide (Revlimid); FDA approval for pazopanib (Votrient)
Please login or register first to view this content.